<DOC>
	<DOC>NCT02881918</DOC>
	<brief_summary>The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head &amp; Neck Squamous Cell Carcinoma Secondary purposes are: - Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs); - Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS - Study of relationship between anti-tumor immune response and clinical stage as well as DFS.</brief_summary>
	<brief_title>Anti-tumor Specific Immune Response in Head and Neck Cancers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Patient with Head &amp; Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage IIV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy) Consent to participate to the study, nonopposition Affiliation to social security History of neoplasia, synchronous cancer, autoimmune disease, organ transplantation, chemotherapy HIV infection Corticotherapy during 15 days before blood sampling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>